140 related articles for article (PubMed ID: 22206665)
1. ETS1 promotes chemoresistance and invasion of paclitaxel-resistant, hormone-refractory PC3 prostate cancer cells by up-regulating MDR1 and MMP9 expression.
Kato T; Fujita Y; Nakane K; Kojima T; Nozawa Y; Deguchi T; Ito M
Biochem Biophys Res Commun; 2012 Jan; 417(3):966-71. PubMed ID: 22206665
[TBL] [Abstract][Full Text] [Related]
2. MiR-34a attenuates paclitaxel-resistance of hormone-refractory prostate cancer PC3 cells through direct and indirect mechanisms.
Kojima K; Fujita Y; Nozawa Y; Deguchi T; Ito M
Prostate; 2010 Oct; 70(14):1501-12. PubMed ID: 20687223
[TBL] [Abstract][Full Text] [Related]
3. Drug resistant breast cancer cells overexpress ETS1 gene.
Kars MD; Işeri OD; Gündüz U
Biomed Pharmacother; 2010 Sep; 64(7):458-62. PubMed ID: 20392592
[TBL] [Abstract][Full Text] [Related]
4. CCR1/CCL5 interaction promotes invasion of taxane-resistant PC3 prostate cancer cells by increasing secretion of MMPs 2/9 and by activating ERK and Rac signaling.
Kato T; Fujita Y; Nakane K; Mizutani K; Terazawa R; Ehara H; Kanimoto Y; Kojima T; Nozawa Y; Deguchi T; Ito M
Cytokine; 2013 Oct; 64(1):251-7. PubMed ID: 23876400
[TBL] [Abstract][Full Text] [Related]
5. The establishment of two paclitaxel-resistant prostate cancer cell lines and the mechanisms of paclitaxel resistance with two cell lines.
Takeda M; Mizokami A; Mamiya K; Li YQ; Zhang J; Keller ET; Namiki M
Prostate; 2007 Jun; 67(9):955-67. PubMed ID: 17440963
[TBL] [Abstract][Full Text] [Related]
6. ETS1 transcriptional activity is increased in advanced prostate cancer and promotes the castrate-resistant phenotype.
Smith AM; Findlay VJ; Bandurraga SG; Kistner-Griffin E; Spruill LS; Liu A; Golshayan AR; Turner DP
Carcinogenesis; 2012 Mar; 33(3):572-80. PubMed ID: 22232738
[TBL] [Abstract][Full Text] [Related]
7. MiR-27a modulates MDR1/P-glycoprotein expression by targeting HIPK2 in human ovarian cancer cells.
Li Z; Hu S; Wang J; Cai J; Xiao L; Yu L; Wang Z
Gynecol Oncol; 2010 Oct; 119(1):125-30. PubMed ID: 20624637
[TBL] [Abstract][Full Text] [Related]
8. Increased nuclear localization of transcription factor Y-box binding protein 1 accompanied by up-regulation of P-glycoprotein in breast cancer pretreated with paclitaxel.
Fujita T; Ito K; Izumi H; Kimura M; Sano M; Nakagomi H; Maeno K; Hama Y; Shingu K; Tsuchiya S; Kohno K; Fujimori M
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8837-44. PubMed ID: 16361573
[TBL] [Abstract][Full Text] [Related]
9. MDR1/P-gp and VEGF synergistically enhance the invasion of Hep-2 cells with multidrug resistance induced by taxol.
Li L; Jiang AC; Dong P; Wang H; Xu W; Xu C
Ann Surg Oncol; 2009 May; 16(5):1421-8. PubMed ID: 19247716
[TBL] [Abstract][Full Text] [Related]
10. MiR-148a attenuates paclitaxel resistance of hormone-refractory, drug-resistant prostate cancer PC3 cells by regulating MSK1 expression.
Fujita Y; Kojima K; Ohhashi R; Hamada N; Nozawa Y; Kitamoto A; Sato A; Kondo S; Kojima T; Deguchi T; Ito M
J Biol Chem; 2010 Jun; 285(25):19076-84. PubMed ID: 20406806
[TBL] [Abstract][Full Text] [Related]
11. SRC tyrosine kinase and multidrug resistance protein-1 inhibitions act independently but cooperatively to restore paclitaxel sensitivity to paclitaxel-resistant ovarian cancer cells.
George JA; Chen T; Taylor CC
Cancer Res; 2005 Nov; 65(22):10381-8. PubMed ID: 16288028
[TBL] [Abstract][Full Text] [Related]
12. Egr-1 enhances drug resistance of breast cancer by modulating MDR1 expression in a GGPPS-independent manner.
Tao W; Shi JF; Zhang Q; Xue B; Sun YJ; Li CJ
Biomed Pharmacother; 2013 Apr; 67(3):197-202. PubMed ID: 23478574
[TBL] [Abstract][Full Text] [Related]
13. Reversal of multidrug resistance by two nordihydroguaiaretic acid derivatives, M4N and maltose-M3N, and their use in combination with doxorubicin or paclitaxel.
Chang CC; Liang YC; Klutz A; Hsu CI; Lin CF; Mold DE; Chou TC; Lee YC; Huang RC
Cancer Chemother Pharmacol; 2006 Nov; 58(5):640-53. PubMed ID: 16544145
[TBL] [Abstract][Full Text] [Related]
14. Reversing drug resistance in the ovarian carcinoma cell line SKOV3/mdr1 in vitro by antisense oligodeoxynucleotides.
Pan L; Tong Y; Jin Y; Zhou S; Zhang Y; Yang X; Mao N
Chin Med J (Engl); 2001 Sep; 114(9):929-32. PubMed ID: 11780384
[TBL] [Abstract][Full Text] [Related]
15. Adenovirus-mediated inhibition of NF-kappaB confers chemo-sensitization and apoptosis in prostate cancer cells.
Flynn V; Ramanitharan A; Moparty K; Davis R; Sikka S; Agrawal KC; Abdel-Mageed AB
Int J Oncol; 2003 Aug; 23(2):317-23. PubMed ID: 12851680
[TBL] [Abstract][Full Text] [Related]
16. A role for SIRT1 in cell growth and chemoresistance in prostate cancer PC3 and DU145 cells.
Kojima K; Ohhashi R; Fujita Y; Hamada N; Akao Y; Nozawa Y; Deguchi T; Ito M
Biochem Biophys Res Commun; 2008 Aug; 373(3):423-8. PubMed ID: 18573234
[TBL] [Abstract][Full Text] [Related]
17. Overcoming paclitaxel resistance in uterine endometrial cancer using a COX-2 inhibitor.
Hasegawa K; Ishikawa K; Kawai S; Torii Y; Kawamura K; Kato R; Tsukada K; Udagawa Y
Oncol Rep; 2013 Dec; 30(6):2937-44. PubMed ID: 24100466
[TBL] [Abstract][Full Text] [Related]
18. The biology of the Ets1 proto-oncogene.
Dittmer J
Mol Cancer; 2003 Aug; 2():29. PubMed ID: 12971829
[TBL] [Abstract][Full Text] [Related]
19. [Chemotherapy resistance induced by interleukin-6 in ovarian cancer cells and its signal transduction pathways].
Wang Y; Li LZ; Ye L; Niu XL; Liu X; Zhu YQ; Sun WJ; Liang YJ
Zhonghua Fu Chan Ke Za Zhi; 2010 Sep; 45(9):691-8. PubMed ID: 21092551
[TBL] [Abstract][Full Text] [Related]
20. Phosphatidylinositol 3'-kinase activation leads to multidrug resistance protein-1 expression and subsequent chemoresistance in advanced prostate cancer cells.
Lee JT; Steelman LS; McCubrey JA
Cancer Res; 2004 Nov; 64(22):8397-404. PubMed ID: 15548710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
